Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Here's Why Incyte (INCY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Incyte (INCY) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What Investors Should Know Before Buying Incyte
Incyte offers a compelling risk-adjusted return profile, outperforming healthcare benchmarks with robust growth and moderate volatility. INCY is successfully transitioning from Jakafi dependence to a diversified Hematology/Oncology, Immunology, and Autoimmunity portfolio, driving double-digit revenue growth. Third-quarter 2025 revenue rose 20% YoY to $1.37B, and operating income was up 204%.
Incyte: Buy For The Turnaround, Stay For The Pipeline
Incyte Corporation earns a Strong Buy rating, with recent execution driving a 56% stock rally and robust revenue growth. Jakafi sales rose 6.7% YoY in Q3 2025, defying terminal decline fears, while ex-Jakafi business surged 45% YoY. Management projects ex-Jakafi revenues to triple by 2030, with pipeline catalysts and Jakafi XR mitigating the 2028 patent cliff.
Incyte's Pipeline Potential Signals Massive Upside For Investors
Incyte is a rare, profitable biotech with earnings doubling since 2021, driven by its core hematology franchise and rapidly expanding dermatology and oncology portfolios. INCY's non-Jakafi portfolio is rapidly expanding, with Opzelura and oncology assets driving double-digit growth and significant margin improvement. Management targets 15–20% five-year sales CAGR and $3–4B ex-Jakafi revenue by 2030, diverging from consensus' negative growth view.
Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report?
Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins
Incyte Corporation remains a Buy, driven by robust Hem/Oncology portfolio growth and key Monjuvi/Minjuvi expansion catalysts. INCY's Hem/Onc portfolio revenues surged 107% YoY in Q3 2025, fueled by Monjuvi/Minjuvi and Niktimvo performance. Positive phase 3 frontMIND data for Monjuvi enables a 1st-line DLBCL sBLA filing in H1 2026, expanding addressable market.
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
